Clinical Trials

Viral immunotherapy for skin cancer shows patient benefit in phase 3 trial

By

A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.

Next-generation ALK-inhibitor brigatinib promising against NSCLC

By

Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).

Evidence grows that melanoma drugs benefit some lung cancer patients

Evidence grows that melanoma drugs benefit some lung cancer patients

By

Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.

Targeting CD20 in chronic lymphocytic leukemia

Targeting CD20 in chronic lymphocytic leukemia

[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.

Personalized melanoma vaccines marshal powerful immune response

By

Personalized melanoma vaccines can be used to galvanize a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.

International study suggests precision medicine has potential in adrenal cancer

By

Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.

Precision medication is effective for subset of adrenal cancer patients

By

A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.

Targeted drug doubles progression-free survival in Hodgkin lymphoma

By

A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.

Combination therapy found best for low-grade brain tumors

By

New evidence indicates that combining chemotherapy with radiation therapy may be the best option for people with a low-grade form of brain cancer.

Cancer survivors need not be excluded from advanced stage lung cancer trials

By

A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .

Immune blockade treatment promising for advanced bladder cancer

By

The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

By

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

By

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

By

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)

By

A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.

IDH1 mutation inhibitor first to demonstrate anticancer activity

By

The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.

Galeterone active in one form of castration-resistant prostate cancer

By

The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).

Researchers identify biological indicator of response to new ovarian cancer drug

By

A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.

Certain cases of advanced colorectal cancer respond better to three-drug regimen

By

Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.

Response to new drug in patients with lymphomas and advanced solid tumors

Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.

Latina patients with breast cancer given more information more likely to enter clinical trials

Latina patients with breast cancer given more information more likely to enter clinical trials

Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.

Personalized cellular therapy leads to complete remission in acute lymphoblastic leukemia

Personalized cellular therapy leads to complete remission in acute lymphoblastic leukemia

By

An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.

Drug targeting glioblastoma to begin clinical trial

By

A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.

New drug for multiple myeloma to begin clinical trial

New drug for multiple myeloma to begin clinical trial

By

A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.

Achieving clinical trial participation through cooperative networks

Achieving clinical trial participation through cooperative networks

By

Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

By

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

PD-L1 a possible immunotherapy target in mesothelioma

By

Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone

Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.

Dabrafenib hitting the target in subset of patients with non-small cell lung cancer

By

The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.

Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study confirms use of trastuzumab for HER2-positive breast cancer

By

The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs